What Is Life Expectancy of Renal Cell Carcinoma
What Is the Life Expectancy of Someone with Renal Cell Carcinoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 27, 2021 Category: General Medicine Source Type: news
Kidney cancer: Two symptoms located on the back warning of the common cancer
KIDNEY cancer, or renal cell cancer, is one of the most common types of cancers in the UK. It usually affects adults in their 60s or 70s. (Source: Daily Express - Health)
Source: Daily Express - Health - October 22, 2021 Category: Consumer Health News Source Type: news
Renal Cell Carcinoma Highlights From ESMO 2021 Renal Cell Carcinoma Highlights From ESMO 2021
Dr Brian Rini, of Vanderbilt University, discusses key RCC abstracts from ESMO 2021, including data on efficacy and quality-of-life endpoints from the STAR, PRISM, and KEYNOTE-564 trials.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 12, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news
New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer.
The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma.
Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making it t...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Adjuvant Pembrolizumab Beneficial in Renal Cell Carcinoma
Rate of disease - free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 19, 2021 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news
Adjuvant Pembrolizumab Beneficial in Renal Cell Carcinoma
THURSDAY, Aug. 19, 2021 -- For patients with clear-cell renal cell carcinoma at high risk for recurrence after nephrectomy, adjuvant therapy with pembrolizumab improves disease-free survival, according to a study published in the Aug. 19 issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 19, 2021 Category: Pharmaceuticals Source Type: news
' Dawn of a New Era' in the Treatment of Renal Cell Carcinoma'Dawn of a New Era' in the Treatment of Renal Cell Carcinoma
Adjuvant pembrolizumab demonstrates significant disease-free survival benefit without excess toxicity in patients at high risk of recurrence.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA OKs Belzutifan for Cancers Tied to von Hippel-Lindau Disease FDA OKs Belzutifan for Cancers Tied to von Hippel-Lindau Disease
The new drug is for patients with von Hippel-Lindau disease who require therapy for a number of associated cancers, including renal cell carcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 13, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
August 11, 2021
Keytruda Plus Lenvima Is Now Approved for Two Types of Cancer, Including Advanced RCC
Based on Phase 3 CLEAR/KEYNOTE-581 Trial, Keytruda Plus Lenvima Significantly Reduced Risk of Disease Progression or Death by 61% Versus... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 11, 2021 Category: Drugs & Pharmacology Source Type: news
Second- and Later-Line Treatment of Metastatic RCC Second- and Later-Line Treatment of Metastatic RCC
When first-line treatments for metastatic renal cell carcinoma fail, what are the next options?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 19, 2021 Category: Consumer Health News Tags: Urology Journal Article Source Type: news
Urine Test Differentiates Kidney Cancer From Benign Lesions Urine Test Differentiates Kidney Cancer From Benign Lesions
For patients with kidney lesions, urine tests under development can differentiate renal cell cancer from benign masses, say investigators.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
ASCO: Pembrolizumab Ups DFS in High-Risk Resected Clear-Cell RCC
FRIDAY, June 4, 2021 -- For patients with fully resected intermediate-high-risk or high-risk clear-cell renal cell carcinoma (ccRCC), adjuvant therapy with pembrolizumab yields a significant and clinically meaningful improvement in disease-free... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2021 Category: Pharmaceuticals Source Type: news
Dana-Farber researchers present key studies at ASCO annual meeting
(Dana-Farber Cancer Institute) Dana-Farber Cancer Institute researchers are presenting at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). Toni K. Choueiri, MD, will present results from the randomized, double-blind, phase III KEYNOTE-564 trial evaluating pembrolizumab versus placebo after surgery in patients with renal cell carcinoma during ASCO's Plenary Session. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2021 Category: Cancer & Oncology Source Type: news
